Spain is represented in the JPIAMR by the National Institute of Health Carlos III (Instituto de Salud Carlos III/ISCIII) and the Directorate General for Scientific and Technical Research of the Ministry of Economy and Competiveness (MINECO). ISCIII is the main funding agency for health research, especially for translational and clinical research. ISCIII programmes include funding for projects, research networks (based on public hospitals, public health institutions and public research institutions), thematic research foundations and human resources. MINECO is the main funding organization for basic and applied research in several related disciplines including Biomedicine, Molecular Biology, Life Sciences, Biotechnology, and Agriculture.
ISCIII participates as partner in the Coordination Action for the JPI AMR while MINECO has declared a participation ‘in-kind’ in this initiative. ISCIII is leading work package 6 on the framework for monitoring and evaluation of the JPI as well as for IPR and regulatory issues. ISCIII will also contribute to the organization of conferences. ISCIII participates in several JPIs in the health field, including Neurodegenerative Diseases (with CDTI) , ISCIII and MINECO participates in Healthy Diet for a Healthy Life, More Years Better Lives and Antimicrobial Resistance. MINECO is coordinating the JPI Water Challenges for a Changing World.
Both Institutions are also actively involved in ERA-NETs related to Health, such as NEURON-II and “Infect-ERA”, which continues previous work in the thematic of Pathogenesis developed by the ERA-NET “Pathogenomics”. ISCIII also participates in E-RARE-2, EuroNanoMed-II, Transcan, ERAsys APP, as well as in TFEU art 185 EDTCP. ISCIII participates in TFEU art 185 AAL (with MINETUR). ISCIII participates in the preparatory phase of five European Infrastructures BBMRI, ECRIN, EATRIS, ELIXIR and ERINHA, having signed for full membership of EATIRS-ERIC and ECRIN-ERIC already. ISCIII also coordinates the project “JPIs To Co-Work” and the project “EU-LAC Health”.